Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Tasly Pharmaceutical Group Co EV-to-EBITDA?
Tasly Pharmaceutical Group CoSHSE:600535 81 EV-to-EBITDA is 12.72 as of Sep. 03, 2026, which is 23% below its 10-year median of 16.60. GuruFocus rates SHSE:600535 with a GF Score™ of 81/100 and a GF Value™ of ¥14.77 (Fairly Valued). The stock has 2 warning signs investors should review. Among 727 Drug Manufacturers companies, Tasly Pharmaceutical Group Co ranks better than 51.72% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tasly Pharmaceutical Group Co's enterprise value is ¥19,172 Mil.
Tasly Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥1,507 Mil. Therefore, Tasly Pharmaceutical Group Co's EV-to-EBITDA for today is 12.72.
The historical rank and industry rank for Tasly Pharmaceutical Group Co's EV-to-EBITDA or its related term are showing as below:
SHSE:600535'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -182.16 Med: 16.6 Max: 27.57
Current: 12.72
During the past 13 years, the highest EV-to-EBITDA of Tasly Pharmaceutical Group Co was 27.57. The lowest was -182.16. And the median was 16.60.
SHSE:600535's EV-to-EBITDA is ranked better than 51.72% of 727
companies
in the Drug Manufacturers industry
Industry Median: 13.53
vs SHSE:600535: 12.72
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Tasly Pharmaceutical Group Co (SHSE:600535) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tasly Pharmaceutical Group Co's PE Ratio (TTM) for today is calculated as:
Tasly Pharmaceutical Group Co's share price for today is ¥14.68.
Tasly Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.820.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tasly Pharmaceutical Group Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tasly Pharmaceutical Group Co's EV-to-EBITDA falls into.
Tasly Pharmaceutical Group Co's current Enterprise Value is ¥19,172 Mil.
Tasly Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,507 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tasly Pharmaceutical Group Co (SHSE:600535) has a EV-to-EBITDA of 12.72 as of Sep. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tasly Pharmaceutical Group Co. This is 23% below median its historical median of 16.60. According to the industry distribution chart, Tasly Pharmaceutical Group Co ranks #351 out of 727 companies in the Drug Manufacturers industry, placing it in the top 48.3%.
Is Tasly Pharmaceutical Group Co's EV-to-EBITDA too high?
Tasly Pharmaceutical Group Co's current EV-to-EBITDA of 12.72 is 23% below median its 10-year median of 16.60. The Drug Manufacturers industry median EV-to-EBITDA is 13.53. Tasly Pharmaceutical Group Co's value of 12.72 is 6% below this industry median. Based on the distribution chart, Tasly Pharmaceutical Group Co ranks #351 out of 727 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tasly Pharmaceutical Group Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tasly Pharmaceutical Group Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tasly Pharmaceutical Group Co ranks #351 out of 727 companies for EV-to-EBITDA. This puts Tasly Pharmaceutical Group Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.53. Tasly Pharmaceutical Group Co's value of 12.72 is 6% below this benchmark. While the company's 10-year median is 16.60 vs. the industry median of 13.53, Tasly Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.53, based on 727 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tasly Pharmaceutical Group Co's current EV-to-EBITDA of 12.72 is 6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tasly Pharmaceutical Group Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tasly Pharmaceutical Group Co's current EV-to-EBITDA is 12.72, which is 23% below median its own 10-year median of 16.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tasly Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co (SHSE:600535) is currently considered Fairly Valued. The stock's GF Value™ is ¥14.77, compared to a current price of ¥14.68 — trading 0.6% below its estimated fair value. The current EV-to-EBITDA is 12.72, which is 23% below median its 10-year median of 16.60 and 6% below the Drug Manufacturers industry median of 13.53. Tasly Pharmaceutical Group Co's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Tasly Pharmaceutical Group Co (SHSE:600535), the current EV-to-EBITDA is 12.72 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥14.68 is trading 0.6% below its estimated GF Value™ of ¥14.77.
GuruFocus considers Tasly Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:600535:
EV-to-EBITDA: 12.72 (23% below median its 10-year median of 16.60)
GF Value™: ¥14.77 vs. price of ¥14.68 (0.6% below fair value)
Industry Position: 6% below the Drug Manufacturers median (#351 of 727)
No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
81GF Score
Get the complete analysis for SHSE:600535
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600535 has been successfully added to your 
